{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:25:02Z","timestamp":1761060302385},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,8,16]]},"abstract":"<jats:p> PURPOSE: Given the activity of prolonged oral etoposide in platinum and paclitaxel-resistant ovarian carcinoma, a phase I trial was conducted that combined increasing days of oral etoposide therapy with paclitaxel and carboplatin in chemotherapy-naive patients with ovarian peritoneal and tubal carcinoma to establish a maximum-tolerated dose (MTD) of this combination. <\/jats:p><jats:p> PATIENTS AND METHODS: Paclitaxel at 175 mg\/m<jats:sup>2<\/jats:sup> given over 3 hours and carboplatin at an area under the curve of 5 were administered on day 1 followed by oral etoposide 50 mg\/m<jats:sup>2<\/jats:sup>\/d beginning on day 2. The number of days of etoposide therapy was escalated on the basis of toxicity. Toxicity end points included neutropenic sepsis, grade 4 thrombocytopenia, or grade 3 neutropenia or thrombocytopenia during etoposide administration. Cycles were repeated every 21 days for a maximum of six courses. Due to hematologic toxicity, the duration of the paclitaxel infusion was decreased to 1 hour for a second stage of accrual. <\/jats:p><jats:p> RESULTS: Of 52 patients studied, 29 were in the first stage of accrual. Dose-limiting toxicity occurred with 8 days of oral etoposide, making the MTD six days of therapy. Twenty-three patients were entered into the second stage of accrual. Dose-limiting toxicity occurred at 12 days of oral etoposide, making the MTD 10 days of therapy. Three patients developed acute myeloid leukemia 16, 27, and 35 months after receiving a cumulative dose of 200 mg\/m<jats:sup>2<\/jats:sup>, 1,200 mg\/m<jats:sup>2<\/jats:sup>, and 2,400 mg\/m<jats:sup>2<\/jats:sup>, respectively. <\/jats:p><jats:p> CONCLUSION: One-hour paclitaxel, carboplatin, and oral etoposide at 50 mg\/m<jats:sup>2<\/jats:sup>\/d for 10 days is tolerable without supportive therapy. The leukemogenic potential is cause for concern and precludes its use in chemotherapy-naive ovarian carcinoma. <\/jats:p>","DOI":"10.1200\/jco.2000.18.16.2957","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:19:48Z","timestamp":1487927988000},"page":"2957-2962","source":"Crossref","is-referenced-by-count":12,"title":["Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study"],"prefix":"10.1200","volume":"18","author":[{"given":"Peter G.","family":"Rose","sequence":"first","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin E.","family":"Greer","sequence":"additional","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira R.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Fowler","sequence":"additional","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P.","family":"McGuire","sequence":"additional","affiliation":[{"name":"From the Division of Gynecologic OncologyDepartment of Obstetrics and Gynecology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus, OH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL; Division of Gynecologic Oncology, University of Washington School of..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0384","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"R2-0384","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.699"},{"key":"R3-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.1.60"},{"key":"R4-0384","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.33"},{"key":"R5-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.405"},{"key":"R6-0384","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050765"},{"key":"R7-0384","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(97)00071-8"},{"key":"R8-0384","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199804000-00006"},{"key":"R9-0384","unstructured":"Perez  EA,  Buckwalter  CA,  Reid  JP:  Combinations of paclitaxel and etoposide in the treatment of lung cancer.  Semin Oncol 23:21,1996\u201325,"},{"key":"R10-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"R11-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1692"},{"key":"R12-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1895"},{"key":"R13-0384","unstructured":"Gore  ME,  Mainwaring  PN,  Macfarlane  V, et al:  A randomized study of high versus standard dose carboplatin in patients (pts) with advanced epithelial ovarian cancer (eoc).  Proc Am Soc Clin Oncol 15:284a,1996  (abstr)"},{"key":"R14-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.193"},{"key":"R15-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.520"},{"key":"R16-0384","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2458::AID-CNCR7>3.0.CO;2-I"},{"key":"R17-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2385"},{"key":"R18-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1333"},{"key":"R19-0384","doi-asserted-by":"publisher","DOI":"10.1007\/BF01209489"},{"key":"R20-0384","unstructured":"Clark  PI,  Cottier  B:  The activity of 10- 14- 21-day schedules of single-agent etoposide in previously untreated patients with extensive small-cell lung cancer.  Semin Oncol 19:36,1992\u201339,   (suppl 14)"},{"key":"R21-0384","unstructured":"Neijt  JP,  Hansen  SW,  Hansen  PG, et al:  Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, III, IV comparing paclitaxel-cisplatin and paclitaxel-carboplatin.  Proc Am Soc Clin Oncol 16:352a,1997  (abstr 1259)"},{"key":"R22-0384","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90490-G"},{"key":"R23-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3386"},{"key":"R24-0384","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5080"},{"key":"R25-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1890"},{"key":"R26-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1897"},{"key":"R27-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1583"},{"key":"R28-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.569"},{"key":"R29-0384","doi-asserted-by":"crossref","unstructured":"Yagita  M,  Ieki  Y,  Onishi  R, et al:  Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.  Int J Oncol 13:91,1998\u201396,","DOI":"10.3892\/ijo.13.1.91"},{"key":"R30-0384","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902043400504"},{"key":"R31-0384","unstructured":"Armstrong  DK,  O\u2019Reilly  S,  Bookman  M, et al:  A phase I study of topotecan, cisplatin and paclitaxel in newly diagnosed epithelial ovarian cancer:  A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 17:350a,1998  (abstr 1351)"},{"key":"R32-0384","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.177"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.16.2957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:00:24Z","timestamp":1653516024000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.16.2957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8,16]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2000,8,16]]}},"alternative-id":["10.1200\/JCO.2000.18.16.2957"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.16.2957","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"subject":[],"published":{"date-parts":[[2000,8,16]]}}}